Search

Displaying results 3051 - 3060 of 6951 in total
  1. Drug

    Zaleplon

    go.drugbank.com/drugs/DB00962
    ApprovedIllicit

    Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. … Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.

    Categories: GABA-A Receptor Agonists, gamma-Aminobutyric Acid A Receptor Agonist
  2. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63814,L63930] Reduced gadolinium exposure is important for patients requiring repeated lifetime imaging - e.g. for multiple sclerosis, spinal conditions, or cancer surveillance - given clinical guidance … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity

  3. Drug

    Deferiprone

    go.drugbank.com/drugs/DB08826
    ApprovedInvestigational

    Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a...

  4. Drug

    Mifepristone

    go.drugbank.com/drugs/DB00834
    ApprovedInvestigational

    Currently under investigation for use in psychotic depression (phase 3 trials). … As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.

    Categories: Hormonal Contraceptives for Systemic Use, Progesterone Receptor Modulators
  5. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  6. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.

  7. Drug

    Tienilic acid

    go.drugbank.com/drugs/DB04831
    ApprovedWithdrawn

    Tienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension.

  8. Drug

    Enoxolone

    go.drugbank.com/drugs/DB13089
    Investigational

    Enoxolone (glycyrrhetic acid) has been investigated for the basic science of Apparent Mineralocorticoid Excess (AME).

    Categories: Preparations for Treatment of Wounds and Ulcers
  9. Drug

    Sodium oxybate

    go.drugbank.com/drugs/DB09072
    ApprovedInvestigational

    [A251430] Due to its physiological effects, sodium oxybate is associated with a risk for substance misuse and abuse. … [A18723] For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries.

  10. Drug

    Gefarnate

    go.drugbank.com/drugs/DB12079
    Investigational

    Gefarnate has been investigated for the treatment and prevention of Stomach Ulcer, Duodenal Ulcer, and Cardio-cerebrovascular Disease.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)